CN1903347A - Medicine composition for treating alimentary canal diseases, prepn. method and application thereof - Google Patents
Medicine composition for treating alimentary canal diseases, prepn. method and application thereof Download PDFInfo
- Publication number
- CN1903347A CN1903347A CN 200610109515 CN200610109515A CN1903347A CN 1903347 A CN1903347 A CN 1903347A CN 200610109515 CN200610109515 CN 200610109515 CN 200610109515 A CN200610109515 A CN 200610109515A CN 1903347 A CN1903347 A CN 1903347A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- pharmaceutical composition
- herba
- radix
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of tablet, soft capsule, capsule, pill, dripping pill, particle, or powder for treating gastroenteritis, gastric ulcer, duodenal ulcer, colitis, etc is prepared from 8 Chinese-medicinal materials including coptis root, amomum fruit, corydalis tuber, aucklandia root, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to treat the pharmaceutical composition of digestive tract disease, relate in particular to pharmaceutical composition of diseases such as treatment stagnation of liver-QI and stomach-QI, acute/chronic gastroenteritis, gastric duodenal ulcer and chronic colitis and its production and application.
Background technology
Digestive tract disease is a kind of commonly encountered diseases and frequently-occurring disease, and the sickness rate of digestive tract disease also has the trend that rises year by year at present.Over year all is multiple such as chronic gastritis, Peptic Ulcers etc., even gastric cancer, closely related in the infection of stomach the inside with helicobacter pylori after deliberation
Along with the change of people's living habit and diet structure, the characteristics of incidence of China's digestive system disease is also and then changing.Not long ago, Nanjing No.1 Hospital's digestive endoscopy center was accepted Endoscopic more than 8000 patients to 2004 in this institute and carried out statistical analysis and find: becoming younger appears in the morbidity of China's digestive tract disease, the trend of westization.In above-mentioned digestive tract disease patient, have people more than 1600 to suffer from stomach, intestinal Peptic Ulcers approximately, and these Peptic Ulcerss patient compare youngly, how between 20～40 years old, minimum patient is also at last kindergarten.Clinical research shows, stress is excessive, do not have breakfast, helicobacter pylori infections etc., all can bring out digestive tract ulcer; The digestive tract ulcer disease takes place in the child, outside the Pass having with inherited genetic factors, also with its love consume oil fried food, sweet food and glutinous food and to eat factor such as vegetable less relevant.Statistical analysis also finds have 25% digestive tract disease patient to suffer from atrophic gastritis approximately.Wherein, there is 8% atrophic gastritis patient may suffer from gastric cancer approximately.If the atrophic gastritis patient merges helicobacter pylori infections, its probability of suffering from gastric cancer more can increase greatly.
At present, the medicine of treatment digestive tract disease is as described below respectively, the Western medicine of treatment diseases associated with inflammation is mainly antibiotics, but antibiotics has serious adverse and has limited its use, Chinese patent medicine for example application number is 03152722.1 the disclosed pharmaceutical composition of Chinese patent application, it is by Endothelium Corneum Gigeriae Galli, Fructus Aurantii (parched), Rhizoma Cyperi (processed with vinegar), Radix Et Rhizoma Rhei, Endoconcha Sepiae, compositions such as Radix Glycyrrhizae, also for example application number is 01138960.5 the disclosed pharmaceutical composition of Chinese patent application, it is by Radix Codonopsis, the Radix Astragali, Poria, Rhizoma Corydalis, Fructus Aurantii, Pericarpium Citri Reticulatae, Fructus Crataegi, Massa Medicata Fermentata, Fructus Hordei Germinatus, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae, Pericarpium Arecae, Rhizoma Chuanxiong, Cortex Magnoliae Officinalis, Radix Curcumae, Semen Raphani, Radix Bupleuri, Radix Gentianae, Rhizoma Cyperi, Rhizoma Alpiniae Officinarum, Fructus Citri, Endoconcha Sepiae, Fructus Amomi, Fructus Aurantii Immaturus, Radix Glycyrrhizae, Olibanum, the Myrrha and the Radix Aucklandiae are made, also for example application number is 97100948.1 the disclosed pharmaceutical composition of Chinese patent application, and it is by Os Sepiae, Pseudobulbus Bletillae (Rhizoma Bletillae), Fructus Aurantii Immaturus, Olibanum, Myrrha, Rhizoma Corydalis, gentamycin, Semen daturae, cimetidine and vitamin are formed.But pharmaceutical composition just is used for treating a certain digestive tract disease, for example chronic gastropathy etc. usually like this.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of digestive tract disease, this medicine is to digestive tract disease, and especially diseases such as stagnation of liver-QI and stomach-QI, acute/chronic gastroenteritis, gastric duodenal ulcer and chronic colitis have curative effect preferably.
The present invention also aims to provide the preparation method and the application of aforementioned pharmaceutical compositions.
The invention provides a kind of pharmaceutical composition for the treatment of digestive tract disease, it is made by raw medicinal materials such as Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis, Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis and the Radix Aucklandiae.
Describe the present invention below.
The weight proportion of raw materials used medical material is preferably: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 100-2000 part, fevervine 100-2000 part, Herba potentillae fulgentis 60-1200 part, Rhizoma Fagopyri Dibotryis 80-1600 part, Rhizoma Coptidis 4-80 part, Fructus Amomi 8-160 part, Rhizoma Corydalis 6-120 part, Radix Aucklandiae 8-160 part;
More preferably: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 200-1000 part, fevervine 200-1000 part, Herba potentillae fulgentis 120-600 part, Rhizoma Fagopyri Dibotryis 160-800 part, Rhizoma Coptidis 8-40 part, Fructus Amomi 16-80 part, Rhizoma Corydalis 12-60 part, Radix Aucklandiae 16-80 part;
Also more preferably: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 400-600 part, fevervine 400-600 part, Herba potentillae fulgentis 200-400 part, Rhizoma Fagopyri Dibotryis 300-500 part, Rhizoma Coptidis 10-30 part, Fructus Amomi 35-45 part, Rhizoma Corydalis 25-35 part, Radix Aucklandiae 30-50 part;
Most preferably be: 500 parts of Radix Campylotropis Hirtella (Herba Myrsines Africanae)s, 500 parts of fevervines, 300 parts of Herba potentillae fulgentis, 400 parts of Rhizoma Fagopyri Dibotryiss, 20 parts of Rhizoma Coptidis, 40 parts of Fructus Amomis, 30 parts of Rhizoma Corydalis, 40 parts of the Radix Aucklandiae.
Raw materials used, Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis, Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis and the Radix Aucklandiae can be buied at pharmacy, and raw materials used medical material and weight thereof are in its decoction pieces after concocting and weight thereof in the literary composition.Can certainly use the fresh feed medical material, its weight needs correspondingly to convert in dehydration ratio in the concocting process.
Pharmaceutical composition of the present invention can be made conventional oral solid formulation (for example tablet, soft capsule, capsule, pill, drop pill, granule, powder etc.).
The invention provides the preparation method of aforementioned pharmaceutical compositions, this method comprises: 1) Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder; 2) Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal material waters are leached, leachate is made clear paste; 3) with 1) middle fine powder and 2) middle clear paste preparation process routinely, change if desired can be used appropriate excipients, makes corresponding oral solid formulation, for example tablet, soft capsule, capsule, pill, drop pill, granule, powder etc.
Wherein, Radix Campylotropis Hirtella (Herba Myrsines Africanae) has and invigorates blood circulation, dispels the wind, manages wet effect, can treat rheumatic arthralgia, has loose bowels, dysentery, stranguria with blood, wait to hinder hemoptysis etc.;
Fevervine has the effect of analgesia, antiinflammatory, expelling wind and removing dampness, promoting blood circulation and detumescence, has analgesic activity and antiinflammatory action;
Herba potentillae fulgentis has the effect of heat clearing and inflammation relieving, cooling blood for hemostasis;
Rhizoma Fagopyri Dibotryis has the effect of antiinflammatory, analgesic, blood stasis dispelling, heat-clearing and toxic substances removing, expelling wind and removing dampness;
Rhizoma Coptidis, cold in nature, bitter in the mouth has the effect of heat clearing and damp drying, eliminating fire and detoxication;
Fructus Amomi, warm in nature, acrid in the mouth.Have removing dampness appetizing, warming spleen and stopping diarrha, the antiabortive effect of regulating the flow of vital energy, Fructus Amomi mainly acts on stomach, kidney and the spleen of human body, can the circulation of qi promoting seasoning, and stomach function regulating is amusing;
Rhizoma Corydalis has another name called Rhizoma Corydalis, Rhizoma Corydalis, corydalis tuber, has the effect of promoting flow of QI and blood, eliminating stasis to stop pain;
The Radix Aucklandiae, in having circulation of qi promoting, transferring, the analgesic effect, be used for heavy behind breast gastral cavity distending pain, the dysentery, food stagnation does not disappear, anorexia.
Pharmaceutical composition of the present invention has effects such as promoting flow of QI and blood and stomach and alleviating pain, and for digestive tract disease, especially the acute/chronic gastroenteritis due to stagnation of liver-QI and stomach-QI, the dampness and heat stasis, gastric and duodenal ulcers, colitis etc. have excellent curative.
The instructions of taking of pharmaceutical composition of the present invention: every day 3 times, at every turn in the 5.49g crude drug.
The specific embodiment
Further describe the present invention below in conjunction with specific embodiment, characteristics of the present invention and advantage will be clearer.These illustrative embodiment only be used for illustrating of the present invention; to protection scope of the present invention without any restriction; it will be understood by those skilled in the art that the substitutions and modifications of doing according to spirit of the present invention any of equal value all fall within the scope of protection of the present invention.
Embodiment 1
Take by weighing Radix Campylotropis Hirtella (Herba Myrsines Africanae) 500g, fevervine 500g, Herba potentillae fulgentis 300g, Rhizoma Fagopyri Dibotryis 400g, Rhizoma Coptidis 20g, Fructus Amomi 40g, Rhizoma Corydalis 30g, Radix Aucklandiae 40g;
Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder;
Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal materials are boiled with the 5L decocting, decoct 2 hours for the first time altogether three times, 1.5 hours for the second time, 1 hour for the third time, merge decoction liquor, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.28～1.35 (50 ℃), add the fine powder of above-mentioned Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae, mixing, drying is pulverized, make granule, tabletting, coating promptly gets tablet.
Embodiment 2
Take by weighing Radix Campylotropis Hirtella (Herba Myrsines Africanae) 400g, fevervine 400g, Herba potentillae fulgentis 200g, Rhizoma Fagopyri Dibotryis 300g, Rhizoma Coptidis 10g, Fructus Amomi 35g, Rhizoma Corydalis 25g, Radix Aucklandiae 30g;
Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder;
Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal materials are boiled with the 7L decocting, decoct 2 hours for the first time altogether three times, 1.5 hours for the second time, 1 hour for the third time, merge decoction liquor, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.28～1.35 (50 ℃), add the fine powder of above-mentioned Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae, mixing, drying is pulverized, and makes granule, packing promptly gets granule.
Embodiment 3
Take by weighing Radix Campylotropis Hirtella (Herba Myrsines Africanae) 200g, fevervine 200g, Herba potentillae fulgentis 600g, Rhizoma Fagopyri Dibotryis 160g, Rhizoma Coptidis 40g, Fructus Amomi 16g, Rhizoma Corydalis 12g, Radix Aucklandiae 16g;
Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder;
With Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal materials boil with the 5L decocting, decoct altogether three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge decoction liquor, filter, get filtrate, filtrate decompression is concentrated into the thick paste that relative density is 1.28～1.35 (50 ℃), add above-mentioned Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the fine powder of the Radix Aucklandiae, mixing, drying, pulverize, add with soybean oil 344g Cera Flava 6g, mixing, cross colloid mill 3 times, with gelatin: glycerol: 100: 35: 95 formulation rubber of water, make soft capsule by pressing, promptly get soft capsule.
Embodiment 4
Take by weighing Radix Campylotropis Hirtella (Herba Myrsines Africanae) 100g, fevervine 100g, Herba potentillae fulgentis 60g, Rhizoma Fagopyri Dibotryis 80g, Rhizoma Coptidis 4g, Fructus Amomi 8g, Rhizoma Corydalis 6g, Radix Aucklandiae 8g;
Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder;
Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal materials are boiled with the 1L decocting, decoct altogether three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge decoction liquor, filter, get filtrate, filtrate decompression is concentrated into the thick paste that relative density is 1.28～1.35 (50 ℃), add the fine powder of above-mentioned Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae, mixing, drying is pulverized, add drop pill substrate, after the fusion, splash in the condensed fluid, choose ball, after the drying, obtain drop pill.
The test example
One, the clinical trial of Drug therapy stagnation of liver-QI and stomach-QI of the present invention or damp-heat congestion type gastroenteropathy
In order to verify the curative effect of pharmaceutical composition of the present invention, to its treatment stagnation of liver-QI and stomach-QI, the damp-heat congestion type gastroenteropathy has carried out clinical trial, and observes in contrast with " stomachache stator ", further investigates its clinical efficacy and safety.Test is carried out in strict accordance with the GCP relevant requirements.The result is as follows:
1 data and method
1.1 the voluntary patient that physical data has selected 40 examples to be diagnosed as stagnation of liver-QI and stomach-QI or damp-heat congestion type gastroenteropathy from hospital outpatient and inpatient participates in test, wherein 20 examples are taken the tablet of the embodiment of the invention 1 and are treated as test group (the open observation); Other 20 examples are organized in contrast, take the stomachache stator and treat.Male 19 examples in the test group, women 1 example, age 19-60 year, average 27.25 ± 10.23 years old, the course of disease 1 day-5 years: male 16 examples in the matched group, women 4 examples, age 19-90 year, average 33.55 ± 12.81 years old, the course of disease 1 day-6 years.Sex distributes, age distribution is learned check, test group and matched group there was no significant difference by statistics.
Meet stagnation of liver-QI and stomach-QI type and damp-heat congestion type gastroenteropathy diagnostic criteria person 1.2 the case choice criteria is all, all can include the test case in.
1. test the complication that undergos surgery in preceding 30 days and cause 1.3 get rid of the case standard; 2. the patient suffers from other diseases, just in medication treatment and influence trial drug observation of curative effect person; 3. deadly infectious disease, bacillary dysentery etc.; 4. gestation or women breast-feeding their children are to this medicine allergy sufferers under-18s or over-65s person the age; 5. merge systemic disease and psychotics such as severe cardiac, liver, kidney; 6. all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment and safety judgement person.
1.4 withdraw from the case standard 1. serious adverse reaction taking place, special complication or physiological change takes place should not continue experimenter's (untoward reaction occurs and answer itemized record); 2. withdraw from (, should count the curative effect statistics) voluntarily as being bolter without reason; 3. experimenter's compliance is poor, violates EXPERIMENTAL DESIGN, does not take medicine in accordance with regulations or merges voluntarily and use other treatment medicine person.
1.5 curative effect judging standard
Clinical cure: took medicine 7 days in, clinical symptom disappearance and lab testing project are normal; Produce effects: took medicine 7 days in, clinical cardinal symptom disappears, other sxs; Perhaps clinical symptom disappearance, routine blood test and/or stool routine examination have unusually in the lab testing project; Effectively: took medicine the part clinical symptom relief 7 days in; Invalid: took medicine 7 days in, clinical symptoms does not have significant change or before increases the weight of, and routine blood test and/or stool routine examination have unusually in the lab testing.
1.6 1. dosage regimen tests medication: the tablet of the embodiment of the invention 1: usage and dosage: oral, 1 time 3,3 times on the 1st, warm water delivery service.2. contrast medication: the stomachache stator: usage and dosage: oral, 1 time 2,3 times on the 1st, warm water delivery service.
1.7 test method adopts single at random blind method, contrast is tested at random.
2 results
2.1 total effects comparative result test group and matched group total effects result are as follows:
| Group | The example number | Clinical cure | Produce effects | Effectively | Invalid | Clinical cure+obvious effective rate | Total effective rate |
| The test group matched group | 20 20 | 5 4 | 8 4 | 6 10 | 1 2 | 65％ 40％ | 95％ 90％ |
Learn check by statistics, matched group and test group compare, the curative effect there was no significant difference.
2.2 test group and matched group observation of symptoms result
| Symptom | Group | The example number | Clinical cure | Produce effects | Effectively | Invalid | Total effective rate |
| Stomachache | The test group matched group | 20 20 | 9 4 | 3 5 | 7 11 | 1 0 | 95％ 100％ |
| Abdominal distention | The test group matched group | 16 16 | 7 5 | 5 6 | 4 3 | 0 2 | 100％ 87.5％ |
| Diarrhoea | The test group matched group | 8 14 | 2 6 | 5 8 | 1 0 | 0 0 | 100％ 100％ |
| Acid regurgitation | Test group | 14 | 4 | 4 | 2 | 4 | 71.4％ |
| Belch | Matched group | 17 | 3 | 8 | 4 | 2 | 88.2％ |
| Have blood in stool | The test group matched group | 0 3 | 0 3 | 0 0 | 0 0 | 0 0 | 0 100％ |
| Mucous Stool | The test group matched group | 0 7 | 0 4 | 0 1 | 0 2 | 0 0 | 0 100％ |
3, discuss
1. test group, matched group patient compare respectively on age, sex, learn check by statistics, P＞0.05, and there was no significant difference points out two groups of cases to have comparability.2. clinical cure+the obvious effective rate of observation of curative effect test group is 65.00%, and total effective rate is 95.00%; Clinical cure+the obvious effective rate of matched group is 40.00%, and total effective rate is 90.00%.Two groups of curative effects are relatively learned check, P＞0.05, there was no significant difference by statistics.Point out two groups of curative effect of medication basically identicals.3. the symptom observation of curative effect is by comparing curative effect index: stomachache, abdominal distention, diarrhoea and acid regurgitation, belch, difference that there are no significant between experimental group and the matched group between six groups of clinical symptoms curative effects are organized.For having blood in stool and two curative effect index of Mucous Stool,, but be 100% to the treatment effective percentage that minority has these two symptoms because test case deficiency can't be carried out statistics relatively.4. process of the test test group and matched group totally 40 routine patients all do not find adverse effect.5. the tablet of the embodiment of the invention 1 is a Chinese patent medicine, has effects such as liver-smoothing, qi-regulating and stomach and alleviating pain, anti-inflammation hemostasia, stopping nausea and vomiting by lowering the adverse flow of QI.Through the hospital clinical test, prove that this medicine has good therapeutical effect to stagnation of liver-QI and stomach-QI type, damp-heat congestion type gastropathy such as acute gastroenteritis, gastric ulcer, duodenal ulcer, chronic colitis, chronic gastroenteritiss, has no adverse reaction.
Two, the clinical trial of medicine composite for curing chronic gastritis of the present invention
In order to verify the curative effect of pharmaceutical composition of the present invention, it has been carried out clinical verification, treat all kinds of chronic gastritis stomachache patients, obtain better effects, the result is as follows.
1 general money section
247 examples are organized in treatment, wherein male 134 examples, women 113 examples; The oldest person 70 years old, reckling 19 years old; The elder of the course of disease is 10 years, and the shortest person is half a year.Chronic superficial gastritis 119 examples wherein, chronic atrophic gastritis 58 examples, bile reflux gastritis 43 examples, chronic erosive gastritis 27 examples.Matched group 100 examples, wherein male 58 examples, women 42 examples; Age reckling 22 years old, the maximum 65 years old; The elder of the course of disease 11 years, the shortest person 1 year.Chronic superficial gastritis 48 examples wherein, chronic atrophic gastritis 16 examples, bile reflux gastritis 25 examples, chronic erosive gastritis 11 examples.
2 Therapeutic Method
Treatment group: the tablet of the oral embodiment of the invention 1, each 3, every day 3 times, taking medicine before meal.6 weeks were 1 course of treatment.
Matched group: oral YUANHU ZHITONG PIAN, each 4, every day 3 times
3 therapeutic outcomes
3.1 criterion of therapeutical effect
Recovery from illness: stomachache transference cure. gastroscope or barium check that thoroughly the mucosa tissue recovery is normal; Produce effects stomachache symptom is sent mistake substantially, and the saturating check of gastroscope or barium takes an evident turn for the better; Take a turn for the better: stomachache before alleviates, and saturating inspection of gastroscope or barium before has improvement; Invalid: the pain that has a stomach-ache does not have improvement or increases the weight of, and gastroscope or barium are checked no change thoroughly.
3.2 result
Treatment is organized in 247 examples, and 111 examples of fully recovering account for 44.9%; Produce effects 60 examples account for 24.3%; 58 examples that take a turn for the better account for 23.5%; Invalid 18 examples, accounting for the 7.3%. total effective rate is 92.7%.
In matched group 100 examples. 20 examples of fully recovering account for 20%; Produce effects 31 examples account for 31%; Effective 3 examples account for 3%; Invalid 12 examples. account for 12%, total effective rate is 88%.
Treatment group cure rate and total effective rate obviously are better than matched group (P＜0.05)
The clinical efficacy of two groups of all kinds of gastritis relatively.
| Symptom | Group | The example number | Clinical cure | Produce effects | Effectively | Invalid | Total effective rate |
| Stomachache | The test group matched group | 20 20 | 9 4 | 3 5 | 7 11 | 1 0 | 95％ 100％ |
| Abdominal distention | The test group matched group | 16 16 | 7 5 | 5 6 | 4 3 | 0 2 | 100％ 87.5％ |
| Diarrhoea | The test group matched group | 8 14 | 2 6 | 5 8 | 1 0 | 0 0 | 100％ 100％ |
| Acid regurgitation | Test group | 14 | 4 | 4 | 2 | 4 | 71.4％ |
| Belch | Matched group | 17 | 3 | 8 | 4 | 2 | 88.2％ |
| Have blood in stool | The test group matched group | 0 3 | 0 3 | 0 0 | 0 0 | 0 0 | 0 100％ |
| Mucous Stool | The test group matched group | 0 7 | 0 4 | 0 1 | 0 2 | 0 0 | 0 100％ |
5 discuss
Gastral cavilty portion pain can be caused by multiple disease. the overwhelming majority is the functional pathological changes of gastric mucosa or stomach.This disease belongs to the category of traditional Chinese medical science gastric abscess.Its cause of disease mostly is eating and drinking without temperance, affection internal injury, overstrain, exopathogen invasion and attack etc. greatly.Cause gastric disorder, its pathogenesis of gastric mucosa injury is nothing more than insufficiency of the spleen. the stagnation of QI. and blood stasis three aspects are principle so control with depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, invigorating the spleen and replenishing QI, removing obstruction in the collateral to relieve pain.Pharmaceutical composition of the present invention is a Chinese patent medicine, has effects such as liver-smoothing, qi-regulating and stomach and alleviating pain, anti-inflammation hemostasia, stopping nausea and vomiting by lowering the adverse flow of QI.Through the hospital clinical test, prove that this medicine has good therapeutical effect to stagnation of liver-QI and stomach-QI type, damp-heat congestion type gastropathy such as acute gastroenteritis, gastric ulcer, duodenal ulcer, chronic colitis, chronic gastroenteritiss, has no adverse reaction.
Claims (9)
1. pharmaceutical composition for the treatment of digestive tract disease, it is made by raw medicinal materials such as Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis, Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis and the Radix Aucklandiae.
2. pharmaceutical composition according to claim 1, it is characterized in that, the weight proportion of described raw medicinal material is: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 100-2000 part, fevervine 100-2000 part, Herba potentillae fulgentis 60-1200 part, Rhizoma Fagopyri Dibotryis 80-1600 part, Rhizoma Coptidis 4-80 part, Fructus Amomi 8-160 part, Rhizoma Corydalis 6-120 part, Radix Aucklandiae 8-160 part.
3. pharmaceutical composition according to claim 1, it is characterized in that, the weight proportion of described raw medicinal material is: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 200-1000 part, fevervine 200-1000 part, Herba potentillae fulgentis 120-600 part, Rhizoma Fagopyri Dibotryis 160-800 part, Rhizoma Coptidis 8-40 part, Fructus Amomi 16-80 part, Rhizoma Corydalis 12-60 part, Radix Aucklandiae 16-80 part.
4. pharmaceutical composition according to claim 1, it is characterized in that, the weight proportion of described raw medicinal material is: Radix Campylotropis Hirtella (Herba Myrsines Africanae) 400-600 part, fevervine 400-600 part, Herba potentillae fulgentis 200-400 part, Rhizoma Fagopyri Dibotryis 300-500 part, Rhizoma Coptidis 10-30 part, Fructus Amomi 35-45 part, Rhizoma Corydalis 25-35 part, Radix Aucklandiae 30-50 part.
5. pharmaceutical composition according to claim 1 is characterized in that, the weight proportion of described raw medicinal material is: 500 parts of Radix Campylotropis Hirtella (Herba Myrsines Africanae)s, 500 parts of fevervines, 300 parts of Herba potentillae fulgentis, 400 parts of Rhizoma Fagopyri Dibotryiss, 20 parts of Rhizoma Coptidis, 40 parts of Fructus Amomis, 30 parts of Rhizoma Corydalis, 40 parts of the Radix Aucklandiae.
6. pharmaceutical composition according to claim 1 is characterized in that, described pharmaceutical composition is oral formulations, for example oral solid formulation.
7. the method for preparing the described pharmaceutical composition of claim 1, this method comprises: 1) Rhizoma Coptidis, Fructus Amomi, Rhizoma Corydalis, the Radix Aucklandiae four flavor raw medicinal materials are ground into fine powder; 2) Radix Campylotropis Hirtella (Herba Myrsines Africanae), fevervine, Herba potentillae fulgentis, Rhizoma Fagopyri Dibotryis four flavor raw medicinal material waters are leached, leachate is made clear paste; 3) with 1) in fine powder and 2) in clear paste preparation process routinely make corresponding oral solid formulation, for example tablet, soft capsule, capsule, pill, drop pill, granule, powder etc.
8. the application of the described pharmaceutical composition of claim 1 in the medicine of preparation treatment digestive tract disease.
9. application according to claim 8 is characterized in that, described digestive tract disease is stagnation of liver-QI and stomach-QI, acute/chronic gastroenteritis, gastric duodenal ulcer or and chronic colitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610109515 CN1903347A (en) | 2006-08-04 | 2006-08-04 | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610109515 CN1903347A (en) | 2006-08-04 | 2006-08-04 | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1903347A true CN1903347A (en) | 2007-01-31 |
Family
ID=37672809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610109515 Pending CN1903347A (en) | 2006-08-04 | 2006-08-04 | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1903347A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319353A (en) * | 2011-09-27 | 2012-01-18 | 井玉生 | Traditional Chinese drug enema for treating abdominal distension after gynecological operation |
| CN103550588A (en) * | 2013-11-10 | 2014-02-05 | 王焕良 | Traditional Chinese medicine preparation for treating chronic gastroenteritis |
| CN108066389A (en) * | 2018-01-10 | 2018-05-25 | 金培林 | A kind of medicinal liquor for treating stomach trouble and preparation method and application |
-
2006
- 2006-08-04 CN CN 200610109515 patent/CN1903347A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319353A (en) * | 2011-09-27 | 2012-01-18 | 井玉生 | Traditional Chinese drug enema for treating abdominal distension after gynecological operation |
| CN102319353B (en) * | 2011-09-27 | 2012-09-26 | 井玉生 | Traditional Chinese drug enema for treating abdominal distension after gynecological operation |
| CN103550588A (en) * | 2013-11-10 | 2014-02-05 | 王焕良 | Traditional Chinese medicine preparation for treating chronic gastroenteritis |
| CN108066389A (en) * | 2018-01-10 | 2018-05-25 | 金培林 | A kind of medicinal liquor for treating stomach trouble and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (en) | Chinese medicine prepn for curing gastropathy radically | |
| CN101874874B (en) | Chinese medicinal preparation for treating helicobacter pylori concerned chronic gastritis and preparation method thereof | |
| CN103495040B (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method of granule formulation thereof | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN103127422B (en) | Medicament for treating ulcerative colitis | |
| CN104940784B (en) | A kind of Chinese medicine composition for treating chronic gastritis | |
| CN100364594C (en) | Medicine for treating chronic superficial gastritis and peptic ulcer diseases | |
| CN103182059B (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN104162129A (en) | Traditional Chinese medicine for treating diabetic gastroparesis | |
| CN1171952A (en) | Traditional Chinese medicine preparation for eradicating Helicobacter phlori | |
| CN101530580B (en) | Drug for curing ulcerative colitis | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN1899570A (en) | Medicine for treating digestive system diseases | |
| CN1168475C (en) | Chinese herbal medicine composition for treating pyloric spirobacterium infected gastropathy and its production process | |
| CN104083747A (en) | Medicinal composition for treating chronic gastritis as well as preparation method and application thereof | |
| CN1259090C (en) | Oral liquid for treating common cold and coughing | |
| CN1130515A (en) | Chinese drug for treating chronic colitis | |
| CN101632777A (en) | Chinese medicinal composition for clearing away heat and toxic material, dispersing food and freeing bowels and preparation method thereof | |
| CN101502597B (en) | Medicament for treating stomachache and preparation method thereof | |
| CN104623152A (en) | Traditional Chinese medicine composition for treating thyroid adenoma due to phlegm-damp stagnation and preparation method thereof | |
| CN1170572C (en) | Medicine for treating atrophic gastritis and chronic colitis and preparation method thereof | |
| CN1907452A (en) | Medicine for treating chronic colitis and its preparing process | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |